Clinical Trials · NCT06195709
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Institut Curie
- Enrollment
- 300
- Start date
- May 2024
- Locations
- 21 sites, France
- Primary endpoint
- Progression-free survival (PFS)